e cadherin (Boster Bio)
Boster Bio is a verified supplier 
Boster Bio manufactures this product 
95
Structured Review
Boster Bio
e cadherin
E Cadherin, supplied by Boster Bio, used in various techniques. Bioz Stars score: 95/100, based on 311 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spatial+transcriptomics+cell-type+deconvolution/Mouse+MMP-2+Recombinant+Protein/pm25066400-22-28-38
Average 95 stars, based on 311 article reviews
E Cadherin, supplied by Boster Bio, used in various techniques. Bioz Stars score: 95/100, based on 311 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spatial+transcriptomics+cell-type+deconvolution/Mouse+MMP-2+Recombinant+Protein/pm25066400-22-28-38
Average 95 stars, based on 311 article reviews
e cadherin - by Bioz Stars,
2026-11
95/100 stars
Images
Related Articles
Over Expression:Article Title: Downregulation of GFPT2 enhances cisplatin chemotherapy sensitivity in STK11/KRAS mutant non-small cell lung cancer by regulating the hexosamine biosynthesis pathway, resisting tumor growth. Article Snippet: Objective: To explore the role of GFPT2 in the sensitivity of STK11/KRAS lung cancer cells to cisplatin chemotherapy, and its underlying mechanism.. Materials & methods: A549 and H460 cells were used to analyze the effect of GFPT2 on cisplatin chemotherapy sensitivity, as both carry KRAS mutations and H460 has LKB1 inactivation mutations, meeting the requirements of a KRAS/LKB1 co mutant tumor model.. The levels of UDP-GlcNAc, OGT, OGA, and O-GlcNAc in the HBP pathway were also determined. CCK-8 Assay:Article Title: Downregulation of GFPT2 enhances cisplatin chemotherapy sensitivity in STK11/KRAS mutant non-small cell lung cancer by regulating the hexosamine biosynthesis pathway, resisting tumor growth. Article Snippet: Objective: To explore the role of GFPT2 in the sensitivity of STK11/KRAS lung cancer cells to cisplatin chemotherapy, and its underlying mechanism.. Materials & methods: A549 and H460 cells were used to analyze the effect of GFPT2 on cisplatin chemotherapy sensitivity, as both carry KRAS mutations and H460 has LKB1 inactivation mutations, meeting the requirements of a KRAS/LKB1 co mutant tumor model.. The levels of UDP-GlcNAc, OGT, OGA, and O-GlcNAc in the HBP pathway were also determined. Cytotoxicity Assay:Article Title: Downregulation of GFPT2 enhances cisplatin chemotherapy sensitivity in STK11/KRAS mutant non-small cell lung cancer by regulating the hexosamine biosynthesis pathway, resisting tumor growth. Article Snippet: Objective: To explore the role of GFPT2 in the sensitivity of STK11/KRAS lung cancer cells to cisplatin chemotherapy, and its underlying mechanism.. Materials & methods: A549 and H460 cells were used to analyze the effect of GFPT2 on cisplatin chemotherapy sensitivity, as both carry KRAS mutations and H460 has LKB1 inactivation mutations, meeting the requirements of a KRAS/LKB1 co mutant tumor model.. The levels of UDP-GlcNAc, OGT, OGA, and O-GlcNAc in the HBP pathway were also determined. Transfection:Article Title: Downregulation of GFPT2 enhances cisplatin chemotherapy sensitivity in STK11/KRAS mutant non-small cell lung cancer by regulating the hexosamine biosynthesis pathway, resisting tumor growth. Article Snippet: Objective: To explore the role of GFPT2 in the sensitivity of STK11/KRAS lung cancer cells to cisplatin chemotherapy, and its underlying mechanism.. Materials & methods: A549 and H460 cells were used to analyze the effect of GFPT2 on cisplatin chemotherapy sensitivity, as both carry KRAS mutations and H460 has LKB1 inactivation mutations, meeting the requirements of a KRAS/LKB1 co mutant tumor model.. The levels of UDP-GlcNAc, OGT, OGA, and O-GlcNAc in the HBP pathway were also determined. Radio Immunoprecipitation:Article Title: Downregulation of GFPT2 enhances cisplatin chemotherapy sensitivity in STK11/KRAS mutant non-small cell lung cancer by regulating the hexosamine biosynthesis pathway, resisting tumor growth. Article Snippet: Objective: To explore the role of GFPT2 in the sensitivity of STK11/KRAS lung cancer cells to cisplatin chemotherapy, and its underlying mechanism.. Materials & methods: A549 and H460 cells were used to analyze the effect of GFPT2 on cisplatin chemotherapy sensitivity, as both carry KRAS mutations and H460 has LKB1 inactivation mutations, meeting the requirements of a KRAS/LKB1 co mutant tumor model.. The levels of UDP-GlcNAc, OGT, OGA, and O-GlcNAc in the HBP pathway were also determined. Lysis:Article Title: Downregulation of GFPT2 enhances cisplatin chemotherapy sensitivity in STK11/KRAS mutant non-small cell lung cancer by regulating the hexosamine biosynthesis pathway, resisting tumor growth. Article Snippet: Objective: To explore the role of GFPT2 in the sensitivity of STK11/KRAS lung cancer cells to cisplatin chemotherapy, and its underlying mechanism.. Materials & methods: A549 and H460 cells were used to analyze the effect of GFPT2 on cisplatin chemotherapy sensitivity, as both carry KRAS mutations and H460 has LKB1 inactivation mutations, meeting the requirements of a KRAS/LKB1 co mutant tumor model.. The levels of UDP-GlcNAc, OGT, OGA, and O-GlcNAc in the HBP pathway were also determined. Acid Assay:Article Title: Downregulation of GFPT2 enhances cisplatin chemotherapy sensitivity in STK11/KRAS mutant non-small cell lung cancer by regulating the hexosamine biosynthesis pathway, resisting tumor growth. Article Snippet: Objective: To explore the role of GFPT2 in the sensitivity of STK11/KRAS lung cancer cells to cisplatin chemotherapy, and its underlying mechanism.. Materials & methods: A549 and H460 cells were used to analyze the effect of GFPT2 on cisplatin chemotherapy sensitivity, as both carry KRAS mutations and H460 has LKB1 inactivation mutations, meeting the requirements of a KRAS/LKB1 co mutant tumor model.. The levels of UDP-GlcNAc, OGT, OGA, and O-GlcNAc in the HBP pathway were also determined. Bicinchoninic Acid Protein Assay:Article Title: Downregulation of GFPT2 enhances cisplatin chemotherapy sensitivity in STK11/KRAS mutant non-small cell lung cancer by regulating the hexosamine biosynthesis pathway, resisting tumor growth. Article Snippet: Objective: To explore the role of GFPT2 in the sensitivity of STK11/KRAS lung cancer cells to cisplatin chemotherapy, and its underlying mechanism.. Materials & methods: A549 and H460 cells were used to analyze the effect of GFPT2 on cisplatin chemotherapy sensitivity, as both carry KRAS mutations and H460 has LKB1 inactivation mutations, meeting the requirements of a KRAS/LKB1 co mutant tumor model.. The levels of UDP-GlcNAc, OGT, OGA, and O-GlcNAc in the HBP pathway were also determined. Enzyme-linked Immunosorbent Assay:Article Title: HDAC6-Mediated NLRP3 Inflammasome Activation Is Involved in Nickel Nanoparticle-Induced Pulmonary Inflammation and Fibrosis. Article Snippet: Nickel nanoparticles (Nano-Ni) are increasingly utilized in industrial and biomedical applications, drawing growing attention to their potential adverse health effects.. Our previous studies have demonstrated that Nano-Ni exposure induces severe, widespread, and persistent pulmonary inflammation and fibrosis.. However, the underlying mechanisms are still unclear. Article Title: Fibroblast-like synoviocytes mediate the generation of soluble PD-1 in an MMP-9-dependent manner: a novel target therapy for rheumatoid arthritis Article Snippet: Human plasma sPD-1 levels were determined using an ELISA kit (R&D Systems, Minneapolis, MN, USA). .. The Clinical Proteomics:Article Title: Fibroblast-like synoviocytes mediate the generation of soluble PD-1 in an MMP-9-dependent manner: a novel target therapy for rheumatoid arthritis Article Snippet: Human plasma sPD-1 levels were determined using an ELISA kit (R&D Systems, Minneapolis, MN, USA). .. The Imaging:Article Title: Apigenin prevents hypertensive vascular remodeling by regulating the TP53 pathway. Article Snippet: Apigenin (ACMEC, ≥97 %, A91020) and Ang II (A9525) were purchased from Sigma-Aldrich (United States). .. MMP9 (1:1000, Boster, PB9669), Western Blot:Article Title: LncPrep + 96kb inhibits ovarian fibrosis by upregulating prolyl oligopeptidase expression Article Snippet: After an incubation with the secondary antibodies at room temperature for 1 h, the protein bands were visualized and semi-quantified using the EasySee Western Blot Kit (cat. no. DW101-01; TransGen Biotech Co., Ltd.) and Image Lab software 3.0 (Bio-Rad Laboratories, Inc.). .. The following antibodies were used for WB: Anti-PREP/POP (1:1,000; cat. no. A00298-2; Bioworld Technology, Inc.), anti-β-actin (1:5,000; cat. no. 66009-1-Ig; Wuhan Sanying Biotechnology), anti-peroxisome proliferator activated receptor γ (PPAR-γ; 1:1,000; cat. no. BA2120; Boster Biological Technology Co., Ltd.), |